X4 Pharmaceuticals (XFOR) Insider Trading & Ownership $0.34 -0.03 (-8.15%) (As of 11/22/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends X4 Pharmaceuticals (NASDAQ:XFOR) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage1.62%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$491,874.90 Get XFOR Insider Trade Alerts Want to know when executives and insiders are buying or selling X4 Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address XFOR Insider Buying and Selling by Quarter Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. X4 Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/15/2024Paula RaganCEOSell31,897$0.56$17,862.32 10/7/2024Adam S. MostafaCFOSell230,645$0.55$126,854.75 10/7/2024Mark BaldryInsiderSell11,127$0.58$6,453.66 10/7/2024Mary DibiaseCOOSell67,695$0.57$38,586.15 10/7/2024Paula RaganCEOSell239,436$0.55$131,689.80 3/11/2024Adam S. MostafaCFOSell52,500$0.88$46,200.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 3/11/2024Arthur TaverasInsiderSell14,235$0.88$12,526.80 3/11/2024Mary DibiaseCOOSell15,409$0.88$13,559.92 3/11/2024Paula RaganCEOSell49,678$0.88$43,716.64 2/12/2024Adam S MostafaCFOSell27,721$1.01$27,998.21 2/12/2024Arthur TaverasInsiderSell787$1.01$794.87 2/12/2024Mary DibiaseCOOSell3,683$1.01$3,719.83 2/12/2024Paula RaganCEOSell21,695$1.01$21,911.95 (Data available from 1/1/2013 forward) XFOR Insider Trading Activity - Frequently Asked Questions Who is on X4 Pharmaceuticals's Insider Roster? The list of insiders at X4 Pharmaceuticals includes Adam S Mostafa, Arthur Taveras, Israel Niv, Mark Baldry, Mary Dibiase, Michael S Wyzga, Murray Stewart, Paula Ragan, and Tuvia Barlev. Learn more on insiders at XFOR. What percentage of X4 Pharmaceuticals stock is owned by insiders? 1.62% of X4 Pharmaceuticals stock is owned by insiders. Learn more on XFOR's insider holdings. Which X4 Pharmaceuticals insiders have been buying company stock? The following insider purchased XFOR shares in the last 24 months: Michael S Wyzga ($30,000.00). How much insider buying is happening at X4 Pharmaceuticals? Insiders have purchased a total of 25,000 XFOR shares in the last 24 months for a total of $30,000.00 bought. Which X4 Pharmaceuticals insiders have been selling company stock? The following insiders have sold XFOR shares in the last 24 months: Adam S Mostafa ($249,621.63), Arthur Taveras ($14,184.71), Israel Niv ($1,401.04), Mark Baldry ($13,941.27), Mary Dibiase ($117,071.47), Murray Stewart ($137,859.36), Paula Ragan ($457,104.09), and Tuvia Barlev ($6,995.24). How much insider selling is happening at X4 Pharmaceuticals? Insiders have sold a total of 1,539,854 X4 Pharmaceuticals shares in the last 24 months for a total of $1,171,233.56 sold. X4 Pharmaceuticals Key ExecutivesDr. Paula Ragan Ph.D. (Age 54)CEO, President & Director Compensation: $1.01MMr. Adam S. Mostafa (Age 44)CFO, Treasurer & Corporate Secretary Compensation: $700.78k1 recent tradesDr. Christophe Arbet-Engels M.B.A. (Age 62)M.D., Ph.D., Chief Medical Officer Compensation: $379.8kDr. Richard Peters M.D. (Age 61)Ph.D., Founder Dr. Renato T. Skerlj Ph.D.FounderDr. Keith T. Flaherty M.D. (Age 53)Founder & Member of Corporate Advisory Board Dr. Mary DiBiase Ph.D. (Age 63)Chief Operating Officer Compensation: $661.59kDr. Arthur Taveras Ph.D. (Age 60)Chief Scientific Officer Dr. Robert David Arbeit (Age 76)Senior Vice President of Clinical Development and Translational Research Mr. Mark Baldry M.B.A. (Age 60)Chief Commercial Officer More Insider Trading Tools from MarketBeat Related Companies Cidara Therapeutics Insider Ownership Atyr PHARMA Insider Ownership Mersana Therapeutics Insider Ownership Fate Therapeutics Insider Ownership Benitec Biopharma Insider Ownership Biomea Fusion Insider Ownership Zentalis Pharmaceuticals Insider Ownership Amarin Insider Ownership Trevi Therapeutics Insider Ownership Solid Biosciences Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:XFOR) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
